James Flinn retweeted
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell #LungCancer @Immutep hubs.li/Q03dkzk-0
James Flinn retweeted
The first patient in our TACTI-004 lung cancer trial has been safely dosed in Australia, marking a significant milestone for the team at @Immutep!
Read the announcement: bit.ly/4j2hd86
#efti #oncology #clinicaltrial #NSCLC
$IMM $IMMP
James Flinn retweeted
CEO Marc Voigt recently caught up with @sharecafetweets to discuss @Immutep's encouraging progress with #efti.
Listen here: bit.ly/3CXhCcv
#NSCLC #biotechnology #oncology
James Flinn retweeted
Sip&Learn Webinar: Immutep's therapies move towards late-stage development
@Immutep $IMM $IMMP
sharecafe.com.au/2025/02/19/…
James Flinn retweeted
We’re pleased to provide our shareholders with a summary of a busy quarter in Q2 FY25, such as our transition to becoming a #PhaseIII biotech.
Read the update: bit.ly/42A1oQI
#biotechnology #LAG3 #immunotherapy
James Flinn retweeted
$IMMP $PRRUF - Immutep Limited: Continuing To Make The Case For Eftilagimod. seekingalpha.com/article/475… #investing #trading #economy
James Flinn retweeted
ICYMI, catch Marc Voigt’s short presentation at @ausbiztv's Investor Connect event at the end of last year. Marc gives a quick snapshot of how @Immutep's lead product candidate fights cancer and how our late-stage clinical trials are tracking.
Watch: bit.ly/3CbPEcn
James Flinn retweeted
Marc Voigt, CEO of @Immutep, was delighted to join @ausbiztv's Investor Event to discuss its recent advancements in cancer treatment and its promising outlook following encouraging trial results.
Watch the short CEO interview: bit.ly/3PvmYhJ
#biotechnology #LAG3
James Flinn retweeted
Here are the under-the-radar stock picks that made the most money in 2024, with speculative ideas proving capable of huge returns. afr.com/markets/equity-marke…
James Flinn retweeted
ICYMI: Tune in to replay of fireside chat with Dr. Martin Forster of the @ucl Cancer Institute and @Immutep CEO Marc Voigt for an overview of recent data in 1L HNSCC patients with PD-L1 CPS <1 and insights into TACTI-004 Phase 3 in #lungcancer
Replay: bit.ly/4iDg5Z1
James Flinn retweeted
Immutep said IMP761 was found safe in initial data from a Phase 1 trial, with no treatment-related adverse events reported. bit.ly/402nf1R #news
James Flinn retweeted
@Immutep is pleased to announce favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating #IMP761.
Read more: bit.ly/3DggWPh
#biotechnology #AutoimmuneDisease #LAG3 #immunotherapy
James Flinn retweeted
@Immutep in collab with @RossjohnLab first to publish structure of LAG-3/HLA-II complex & resolve how human LAG-3 binds to its main ligand, providing better foundation for development of blocking #LAG3 therapeutics incl its own small molecule program.
bit.ly/3DkXnp2
James Flinn retweeted
@Immutep is proud to report new positive results from efti in combination with KEYTRUDA® at #ESMOIO2024 in first line #HNSCC patients with PD-L1 expression below 1 (CPS <1). Data shows strong overall & progression-free survival and durability.
Read more: bit.ly/3Zx0cuz
James Flinn retweeted
Immutep (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck.
finnewsnetwork.com.au/archiv…
$IMM @Immutep
James Flinn retweeted
Immutep (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck.
finnewsnetwork.com.au/archiv…
$IMM @Immutep
James Flinn retweeted
@Immutep is pleased to share an Investor Update discussing the upcoming TACTI-004 trial & becoming a Phase 3 biotech. The potential for efti combined with KEYTRUDA & chemo is to set a new standard-of-care in #NSCLC
Read more here: bit.ly/4eRmFb8
#LungCancerAwarenessMonth
James Flinn retweeted
Eftilagimod alpha plus pembrolizumb and chemotherapy generated favorable survival data in nonsquamous NSCLC. #lcsm #MedEd
Read here: onclive.com/view/eftilagimod…
James Flinn retweeted
In the phase 1 INSIGHT-003 trial, the combination of eftilagimod alpha, pembrolizumab, and chemotherapy showed promising results in terms of overall survival & progression-free survival in metastatic nonsquamous #NSCLC. #lcsm
targetedonc.com/view/eftilag…
James Flinn retweeted
Immutep’s LAG-3 Adds To Keytruda In First-Line Lung Cancer ow.ly/8Ey7105OYXA #PharmaScrip

















